Drug Discovery Today delivers informed and highly current reviews for the discovery community. The magazine addresses not only
the rapid scientific developments in drug discovery associated technologies but also the management, commercial and regulatory issues
that increasingly play a part in how R&D is planned, ... click here for full Aims & Scope
Drug Discovery Today delivers informed and highly current reviews for the discovery community. The magazine addresses not only
the rapid scientific developments in drug discovery associated technologies but also the management, commercial and regulatory issues
that increasingly play a part in how R&D is planned, structured and executed.
Features include comment by international experts,
news and analysis of important developments, reviews of key scientific and strategic issues, overviews of recent progress in specific
therapeutic areas and conference reports.
Coverage includes:
• Novel therapeutic strategies
• High-throughput
screening
• Therapeutic targets
• Combinatorial chemistry, parallel synthesis and library design
• Drug
delivery
• ADME/Tox
• Advances in key compound classes and therapeutic areas
• Genomics and proteomics
• Automation and technology
• Virtual chemistry
• Informatics
• Business strategy
•
Clinical trials
and other aspects of drug discovery.
Ethics in Publishing: General Statement
The Editor(s)
and Publisher of this Journal believe that there are fundamental principles underlying scholarly or professional publishing. While this
may not amount to a formal 'code of conduct', these fundamental principles with respect to the authors' paper are that the paper should:
i) be the authors' own original work, which has not been previously published elsewhere, ii) reflect the authors' own research and analysis
and do so in a truthful and complete manner, iii) properly credit the meaningful contributions of co-authors and co-researchers, iv)
not be submitted to more than one journal for consideration, and v) be appropriately placed in the context of prior and existing research.
Of equal importance are ethical guidelines dealing with research methods and research funding, including issues dealing with informed
consent, research subject privacy rights, conflicts of interest, and sources of funding. While it may not be possible to draft a 'code'
that applies adequately to all instances and circumstances, we believe it useful to outline our expectations of authors and procedures
that the Journal will employ in the event of questions concerning author conduct. With respect to conflicts of interest, the Publisher
now requires authors to declare any conflicts of interest that relate to papers accepted for publication in this Journal. A conflict
of interest may exist when an author or the author's institution has a financial or other relationship with other people or organizations
that may inappropriately influence the author's work. A conflict can be actual or potential and full disclosure to the Journal is the
safest course. All submissions to the Journal must include disclosure of all relationships that could be viewed as presenting a potential
conflict of interest. The Journal may use such information as a basis for editorial decisions and may publish such disclosures if they
are believed to be important to readers in judging the manuscript. A decision may be made by the Journal not to publish on the basis
of the declared conflict.
For more information, please refer to: 
http://www.elsevier.com/wps/find/authorshome.authors/conflictsofinterest
Hide Aims & Scope
Editor: Contact the Editor
Stephen Carney
Visit the Drug Discovery Today website
Home | Elsevier Sites | Privacy Policy | Terms and Conditions | Feedback | Site Map | A Reed Elsevier Company